Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor–naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
- Resource Type
- Article
- Source
Journal of Chemotherapy (Taylor & Francis Ltd) . Apr2022, Vol. 34 Issue 2, p87-96. 10p.- Subject
- Language
- ISSN
- 1120-009X